Abivax’ €12 Million Capital Raising


Dechert advised Abivax on the deal.

Abivax is a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer.

The Company completed a €12M capital increase entirely subscribed at market price by Sofinnova Crossover I, a fund managed by Sofinnova Partners.

This capital increase enables Abivax, now valued at more than €100 million, to secure funding for its clinical trials until mid-2020.

Dechert advise Abivax with a team led by Alain Decombe (Picture) and Charles Cardon, with assistance from Quentin Durand and Vianney Toulouse.

Involved fees earner: Charles Cardon – Dechert; Alain Decombe – Dechert; Quentin Durand – Dechert; Vianney Toulouse – Dechert;

Law Firms: Dechert;

Clients: Abivax;